CS
LYEL icon

Comerica Securities’s Lyell Immunopharma LYEL Stock Holding History

Comerica Securities’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$156 – 1003
2022
Q4 		$156 Buy
+2
New +$199 ﹤0.01% 1497

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Comerica Securities's LYEL Position: Q1 2023 in Review

Comerica Securities sold out of Lyell Immunopharma (LYEL) in Q1 2023, closing a stake of 2 shares — an estimated $156 sold.

Comerica Securities first reported a position in LYEL in Q4 2022 and held it in 1 quarter. The position peaked at $156 in Q4 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q1 2023.

  • Comerica Securities reported no remaining Lyell Immunopharma position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 2 Lyell Immunopharma shares in Q1 2023, an estimated $156.
  • Comerica Securities first reported a position in Lyell Immunopharma in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Lyell Immunopharma position peaked at $156 in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.